Scholarlink

<p>Transposable elements (TEs), which are under tight epigenetic control, have been co-opted as cis-regulatory elements to regulate gene expression during development and cancer. Among them, long interspersed element 1 (LINE-1) retrotransposons are the most abundant and exhibit high activity in embryonic stem cells. However, the precise role of LINE-1 in breast cancer stem cells (BCSCs) remains poorly understood. Here, using RNA sequencing, an enhancer dual-luciferase reporter assay, and a nuclease-dead Cas9 (dCas9)-based CRISPR activation (CRISPRa) assay, we show that the LINE-1 retrotransposon L1Md_T within <i>Sema3c</i> (<i>Sema3c</i>_L1Md_T) is derepressed and functions as a <i>cis</i>-regulatory enhancer that drives SEMA3C expression to sustain mouse BCSC survival. In mouse BCSCs, <i>Sema3c</i>_L1Md_T results in the formation of more phase-separated nuclear condensates with the transcriptional coactivator BRD4 under conditions of increased chromatin accessibility. BRD4 puncta coincide with regions marked by histone H3 lysine 27 acetylation (H3K27ac), enhancing the transcription of SEMA3C. Aberrant SEMA3C expression contributes to mouse BCSC survival and self-renewal via its receptor NRP1 and the coreceptors PlexinA2/PlexinD1. Importantly, we also demonstrate that this regulatory mechanism is conserved in human breast cancer, where SEMA3C is highly expressed in human BCSCs. A human LINE-1 element (SEMA3C_L1ME4a) exhibits enhancer activity and colocalizes with BRD4 condensates in human BCSCs. These findings confirm that the LINE1-BRD4-SEMA3C regulatory axis is present in both mouse and human BCSCs, underscoring its translational relevance. Notably, pharmacological degradation of BRD4 using the proteolysis-targeting chimaera (PROTAC) MZ1 reduces SEMA3C levels and decreases BCSC viability both <i>in vitro</i> and <i>in vivo.</i> Our study reveals an oncogenic role for a LINE-1-derived enhancer in regulating SEMA3C transcription and sustaining BCSC properties, highlighting BRD4 as a therapeutic vulnerability in BCSC-driven breast cancer progression.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

A LINE-1 retrotransposon promotes SEMA3C expression as a cis-regulatory enhancer to sustain breast cancer stem cell survival

  • 期刊论文

  • 发表日期：

    2026年4月10日

查看全文
  • Qidong Xia,
  • Jingwei Feng,
  • Jiayao Pan,
  • Wen Deng,
  • Xiaoqi Weng,
  • Jianhui Jiang,
  • Lin Wang,
  • Wenqian Xie,
  • Yi Chen,
  • Aiwei Bi,
  • Jiang Li,
  • Yiwen Lu,
  • Shicheng Su

摘要

Transposable elements (TEs), which are under tight epigenetic control, have been co-opted as cis-regulatory elements to regulate gene expression during development and cancer. Among them, long interspersed element 1 (LINE-1) retrotransposons are the most abundant and exhibit high activity in embryonic stem cells. However, the precise role of LINE-1 in breast cancer stem cells (BCSCs) remains poorly understood. Here, using RNA sequencing, an enhancer dual-luciferase reporter assay, and a nuclease-dead Cas9 (dCas9)-based CRISPR activation (CRISPRa) assay, we show that the LINE-1 retrotransposon L1Md_T within Sema3c (Sema3c_L1Md_T) is derepressed and functions as a cis-regulatory enhancer that drives SEMA3C expression to sustain mouse BCSC survival. In mouse BCSCs, Sema3c_L1Md_T results in the formation of more phase-separated nuclear condensates with the transcriptional coactivator BRD4 under conditions of increased chromatin accessibility. BRD4 puncta coincide with regions marked by histone H3 lysine 27 acetylation (H3K27ac), enhancing the transcription of SEMA3C. Aberrant SEMA3C expression contributes to mouse BCSC survival and self-renewal via its receptor NRP1 and the coreceptors PlexinA2/PlexinD1. Importantly, we also demonstrate that this regulatory mechanism is conserved in human breast cancer, where SEMA3C is highly expressed in human BCSCs. A human LINE-1 element (SEMA3C_L1ME4a) exhibits enhancer activity and colocalizes with BRD4 condensates in human BCSCs. These findings confirm that the LINE1-BRD4-SEMA3C regulatory axis is present in both mouse and human BCSCs, underscoring its translational relevance. Notably, pharmacological degradation of BRD4 using the proteolysis-targeting chimaera (PROTAC) MZ1 reduces SEMA3C levels and decreases BCSC viability both in vitro and in vivo. Our study reveals an oncogenic role for a LINE-1-derived enhancer in regulating SEMA3C transcription and sustaining BCSC properties, highlighting BRD4 as a therapeutic vulnerability in BCSC-driven breast cancer progression.